Myocardial infarction from non-obstructive coronary arteries (MINOCA); This literature-non-study case was reported in a literature article and describes the occurrence of ACUTE MYOCARDIAL INFARCTION (Myocardial infarction from non-obstructive coronary arteries (MINOCA)) in a 71-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.       No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACUTE MYOCARDIAL INFARCTION (Myocardial infarction from non-obstructive coronary arteries (MINOCA)) (seriousness criterion medically significant). At the time of the report, ACUTE MYOCARDIAL INFARCTION (Myocardial infarction from non-obstructive coronary arteries (MINOCA)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Catheterisation cardiac: Showed no angiographically significant coronary artery disease. On an unknown date, Echocardiogram: Showed left-ventricular ejection-fraction (LVEF) of 55-60%, with no wall motion abnormalities. On an unknown date, Electrocardiogram: Showed diffuse ST depression suggestive of subendocardial ischemia. On an unknown date, Troponin I: peak level 7.75 ng/mL.     For mRNA-1273 (Spikevax) (Unknown), the reporter considered ACUTE MYOCARDIAL INFARCTION (Myocardial infarction from non-obstructive coronary arteries (MINOCA)) to be related.    No concomitant and treatment medications were reported.  Patient received second dose of mRNA-1273 COVID (Moderna) vaccine and presented with shortness of breath.  Author concluded that the cardiac injury would be primarily caused by a hyperinflammatory response and might not be viral myocardial infiltration itself. The mRNA vaccines, like SARS-CoV-2 infection elicits an immune response that attacks the myocardium and author believed that Myocardial infarction from non-obstructive coronary arteries (MINOCA) should be reported as an adverse reaction to the vaccine.  Company Comment: This is a literature non-study case concerning a 71-year-old, female patient with no reported medical history, who experienced the serious (due to medically significant) unexpected, AESI of acute myocardial infarction (reported as infarction from non-obstructive coronary arteries). The event occurred after the second dose of mRNA-1273 vaccine. Patient received second dose of mRNA-1273 COVID (Moderna) vaccine and presented with shortness of breath. Relevant diagnostic tests included cardiac catheterisation cardiac that showed no angiographically significant coronary artery disease, echocardiogram that showed left-ventricular ejection-fraction (LVEF) of 55-60% (reference ranges not provided), with no wall motion abnormalities (no reference ranges provided), electrocardiogram showed diffuse ST depression suggestive of subendocardial ischemia and peak troponin I level of 7.75 ng/mL peak level (reference ranges not provided). At the time of the report the event outcome was unknown. The outcome of the event was reported as unknown and the treatment for the event was not provided. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-715568.   Most recent FOLLOW-UP information incorporated above includes: On 16-Mar-2023: Live follow up received by safety on 16-Mar-2023 has email and contains new updates: Citation details and reporter details were added.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-715568:93 Year Old Female Case